SUMMARY Placebo and topical atenolol (Tenormin), a selective pl-adrenergic blocking substance with no intrinsic sympathomimetic or membrane-stabilising properties, were tested in 16 patients with ocular hypertension in a double-blind cross-over trial. Three different concentrations of atenolol (1, 2, and 4 %) were investigated. After a single instillation there was a statistically significant fall in mean intraocular pressure (IOP) with all the concentrations after one hour, with a maximum after two to three hours. The effect had passed off after seven hours. In multiple-dose studies with applications three times a day for seven days there was a statistically significant fall in the mean IOP on the first day of treatment (all three concentrations), which persisted throughout the week.
In the single-dose study only a slight dose-dependence was observed. This could not be confirmed in the multiple-dose trial. Pupil size, corneal sensitivity, systemic blood pressure, and heart rate were unaffected. No side effects were noted. Thus topically applied atenolol lowers IOP in patients with ocular hypertension and may be clinically useful.
Propranolol, a f3-adrenergic blocking agent which inhibits both f1 receptors (cardiac receptors) and P2 receptors (broncho-and vasodilatating receptors), has an ocular hypotensive action when given systemically (Phillips et al., 1967; Cote and Drance, 1968; Vale and Phillips, 1970; Ohrstrom, 1973; Pandolfi and Ohrstr6m, 1974; Sharaf et al., 1974; Wettrell and Pandolfi, 1975; Borthne, 1976; Wettrell and Pandolfi, 1976; Wettrell et al., 1977) . Practolol (a selective P1 antagonist but with some intrinsic sympathomimetic activity) acts in the same way (Hagedorn and Tjoa, 1974; Wettrell and Pandolfi, 1975; Wettrell et al., 1977) . A fall in ocular tension has also been reported after topical application of propranolol and practolol (Musini et al., 1971; Bietti, 1972; Vale et al., 1972; Vale and Phillips, 1973) . The mode of action is unknown but in the case of propranolol has been ascribed to secondary effects such as membrane stabilisation (Musini et al., 1971) .
Recently another beta-blocking compound, atenolol (Tenormin) (Fig. 1) , a selective inhibitor of P, receptors, has been introduced. Unlike practolol and propranolol it has neither intrinsic activity nor membrane-stabilising properties (Barrett et al., 1973) , but when given by mouth it lowers intraocular pressure (IOP) (Elliot et al., 1975; Wettrell and Pandolfi, 1975; Wettrell et al., 1977) . There have been no re-
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No changes in pupil size, systemic blood pressure, or heart rate were apparent.
On the first day of treatment there was a distinct, statistically significant fall in mean IOP at noon with all concentrations of atenolol ( Table 2 ). The mean fall was 2-4, 2-6, and 3-4 mmHg for 1, 2, and 4% concentrations respectively. The fall persisted and was statistically significant throughout the week, although the response tended to diminish at the end of the period ( Table 2 ). The fall did not seem to be dose-dependent. A slight placebo effect was noted (Table 3 , Fig. 4 ). Corneal sensitivity, systemic blood pressure, and heart rate were unaffected. The patients did not report any local or general side effects, and there were no signs of intolerance to the drug.
Discussion
This study shows that atenolol lowers IOP when applied topically in patients with ocular hypertension, as others have previously reported that it does when taken by mouth (Elliot et al., 1975; Wettrell and Pandolfi, 1975; Wettrell et al., 1977) . Elliot et al. (1975) reported that IOP fell one hour after a single oral dose of 50 mg atenolol with a maximum fall after five hours.
We found that IOP fell one hour after topical application of atenolol and that the fall reached a maximum after two to three hours. A similar time course has been described with other topically administered f antagonists such as propranolol, practolol, pindolol, and oxprenolol (Vale et al., 1972; Vale and Phillips, 1973; Bonomi and Steindler, 1975; Bucci, 1976) , but these substances have caused side effects such as hyperaemia of the conjunctiva and discomfort. Unlike propranolol, atenolol has no membrane stabilising properties. Thus it had no effect on In our multiple-dose study the fall in IOP was less than the maximum effect in the single-dose trial. Nevertheless, in the multiple-dose study IOP was measured at noon-that is, about five hours after the first application of atenolol and immediately before the second application. Therefore, judging from the single-dose study, the maximum effect had already passed and the IOP was recorded in the recovery phase.
In the multiple-dose study a tendency to tachyphylaxis to the drug was observed at the end of the treatment. This diminished drug response was more pronounced in the diurnal measurements of IOP on the same day. Similar phenomena have been described after treatment with adrenergic substances such as salbutamol and epinephrine Paterson, 1971, 1972; Langham, 1974; Langham and Diggs, 1974; Langham, 1975 
